Compare Enveric Biosciences Inc (ENVB) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs TJX Companies Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while TJX Companies Inc trades at $138.21 (market cap $152.62B). The key difference: TJX Companies Inc is far larger — about 22444.1× Enveric Biosciences Inc's market cap, and TJX Companies Inc pays a 1.38% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and TJX Companies Inc for 97 Days on average.
| ENVB | TJX | |
|---|---|---|
Market Cap | $6.80M | $152.62B |
Volume | 64,867 | 8,079,794 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $168.41 |
52-Week Low | $1.27 | $122.84 |
Typical Hold Time | 14 Days | 97 Days |
Enterprise Value | -$1.49M | $160.93B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
TJX trades at $138.80, up 1.28% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong fundamentals with consistent revenue growth, reaching $56.36B in 2025, and robust profitability with a 9.73% net margin. Recent quarters have seen earnings beats, and analyst consensus is overwhelmingly positive with an average price target of $174.15, implying significant upside.
The outlook for TJX is favorable, supported by earnings momentum and Wall Street optimism. Key risks include competitive pressures in off-price retail and sensitivity to consumer spending trends. The stock's high valuation multiples require sustained growth to justify current levels, but strong cash flow and expansion prospects present a compelling case for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
